DIM as a Treatment for Thyroid Disease
关键词
抽象
日期
| 最后验证: | 03/31/2013 |
| 首次提交: | 04/29/2013 |
| 提交的预估入学人数: | 04/29/2013 |
| 首次发布: | 05/02/2013 |
| 上次提交的更新: | 04/29/2013 |
| 最近更新发布: | 05/02/2013 |
| 实际学习开始日期: | 10/31/2006 |
| 预计主要完成日期: | 07/31/2011 |
| 预计完成日期: | 08/31/2011 |
状况或疾病
干预/治疗
Dietary Supplement: A
相
手臂组
| 臂 | 干预/治疗 |
|---|---|
| Experimental: A Subjects with proliferative thyroid disease | Dietary Supplement: A 300 mg of Bioresponse DIM (100mg/day of active DIM) a day for 30 days |
资格标准
| 有资格学习的年龄 | 18 Years 至 18 Years |
| 有资格学习的性别 | All |
| 接受健康志愿者 | 是 |
| 标准 | Inclusion Criteria: - Adults diagnosed with abnormalities of the thyroid gland suspicious for benign adenoma, or goiterous changes. Exclusion Criteria: - Patients who are pregnant, attempting to conceive, or lactating will be excluded due to possible deleterious effects of treatment on fetus/infant. Patients taking oral contraceptives, estrogen therapy, tamoxifin or those with a history of breast cancer will be excluded. Patients with liver disease and those taking statins for hypercholesterolemia will also be excluded to decrease the potential for possible liver toxicity. Any patient with elevated liver enzymes on pretreatment blood screening will be excluded from study participation. Patients with serious systemic diseases such as renal failure, diabetes, blood dyscrasia, coagulopathy, and non-optimized cardiopulmonary disease will be excluded due to the possibility of confounding blood tests screening for toxicity. |
结果
主要结果指标
1. Evidence of objective and quantifiable changes in thyroid size as a resalt of the oral administration of DIM, confirmed by pre- and post- DIM treatment ultrasounds [after 30 days of DIM consumption and 2 and 4 weeks after DIM consumption stopped]
次要成果指标
1. Evidence of DIM's effect on estrogen metabolites, confirmed by plasma and urine analysis [after 30 days of DIM consumption]
